Rinvoq (upadacitinib) is a once-daily extended-release tablet approved for treating moderate to severe rheumatoid arthritis in adults. It's specifically designed for people who haven't responded well to methotrexate alone.
The medication works by targeting and inhibiting a specific protein in your body called JAK1, which Show Full Answer
Rinvoq (upadacitinib) is a once-daily extended-release tablet approved for treating moderate to severe rheumatoid arthritis in adults. It's specifically designed for people who haven't responded well to methotrexate alone.
The medication works by targeting and inhibiting a specific protein in your body called JAK1, which is involved in inflammation. You can take it either by itself or combined with methotrexate. The FDA approved Rinvoq for treating RA in August 2019. Like other medications in its class (JAK inhibitors), it has been shown to help slow down irreversible joint damage. This makes it an important treatment option for people who haven't found success with other RA medications.
August 21, 2025
Join
Your Privacy Choices
